Difference between revisions of "Stephen Moses"

From IntactiWiki
Jump to navigation Jump to search
m (wikify HIV)
(Active projects: Wikify.)
 
(6 intermediate revisions by 2 users not shown)
Line 70: Line 70:
 
  |title=Dr. Stephen Moses
 
  |title=Dr. Stephen Moses
 
  |url=http://umanitoba.ca/faculties/medicine/units/medical_microbiology/faculty/StephenMoses.html
 
  |url=http://umanitoba.ca/faculties/medicine/units/medical_microbiology/faculty/StephenMoses.html
  |publisher=University of Manitoba
+
  |publisher={{UNI|University of Manitoba|UManitoba}}
 
  |date=
 
  |date=
 
  |accessdate=2011-02-23
 
  |accessdate=2011-02-23
Line 80: Line 80:
 
  |last=
 
  |last=
 
  |first=
 
  |first=
  |publisher=Doctors Opposing Circumcision
+
  |publisher=[[Doctors Opposing Circumcision (D.O.C.)]]
 
  |date=2016
 
  |date=2016
 
  |title=HIV/AIDS
 
  |title=HIV/AIDS
 
  |url=https://www.doctorsopposingcircumcision.org/for-professionals/alleged-medical-benefits/hivaids/
 
  |url=https://www.doctorsopposingcircumcision.org/for-professionals/alleged-medical-benefits/hivaids/
 
  |accessdate=2020-03-23
 
  |accessdate=2020-03-23
}}</ref>Of the three {{#tip-text:RCT|Randomized controlled trial}}s being used by the [[WHO]] to endorse circumcision as [[HIV]] prevention, Stephen Moses and [[Robert C. Bailey]] headed the {{#tip-text:RCT|Randomized controlled trial}} that was carried out in Kenya.<ref>Bailey RC, Moses S, Parker CB, et al. Male circumcision for [[HIV]] prevention in young men in Kisumu, Kenya: a randomised controlled trial. ''Lancet'' 2007;369:643-56. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60312-2/abstract Abstract]</ref> Moses obviously brought his pre-existing bias in favor of male circumcision into the trial, so he did not start from a neutral position.
+
}}</ref>Of the three {{#tip-text:RCT|Randomized controlled trial}}s being used by the [[WHO]] to endorse circumcision as [[HIV]] prevention, Stephen Moses and [[Robert C. Bailey]] headed the {{#tip-text:RCT|Randomized controlled trial}} that was carried out in Kenya.<ref>{{RCT Bailey et al 2007}}</ref> Moses obviously brought his pre-existing bias in favor of male circumcision into the trial, so he did not start from a neutral position.
  
Moses' research on circumcision protection from [[HIV]] infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent ''relative'' reduction in [[HIV]] was claimed, the ''absolute'' reduction was a statistically insignificant 1.3 percent.<ref name="boyle-hill2011">{{BoyleGJ HillG 2011}}</ref> Garenne & Matthews (2019) report that circumcised men have as much [[HIV]] infection as intact men.<ref>{{REFjournal
+
Moses' research on circumcision protection from [[HIV]] infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent ''relative'' reduction in [[HIV]] was claimed, the ''absolute'' reduction was a statistically insignificant 1.3 percent.<ref name="boyle-hill2011">{{BoyleGJ HillG 2011}}</ref> [[Michel Garenne|Garenne]] & Matthews (2019) report that circumcised men have as much [[HIV]] infection as intact men.<ref>{{REFjournal
 
  |last=Garenne
 
  |last=Garenne
 
  |init=M
 
  |init=M
  |author-link=
+
  |author-link=Michel Garenne
 
  |last2=Matthews
 
  |last2=Matthews
 
  |init2=A
 
  |init2=A
Line 115: Line 115:
 
* A randomized, controlled trial of male circumcision to reduce [[HIV]] incidence in Kisumu, Kenya.<ref name='moses-bio'/><br><small>[[National Institutes of Health]].</small>
 
* A randomized, controlled trial of male circumcision to reduce [[HIV]] incidence in Kisumu, Kenya.<ref name='moses-bio'/><br><small>[[National Institutes of Health]].</small>
 
* Scaling up [[HIV]] prevention in Karnataka and southern Maharashtra, Phase II.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
 
* Scaling up [[HIV]] prevention in Karnataka and southern Maharashtra, Phase II.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
* Monitoring and evaluation of the Avahan project in India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
+
* Monitoring and evaluation of the Avahan project in [[India]].<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
* Technical assistance to improve maternal, neonatal & child health through National Rural Health Mission, India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
+
* Technical assistance to improve maternal, neonatal & child health through National Rural Health Mission, [[India]].<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
 
* Mapping key populations for [[HIV]] prevention in Sri Lanka.<ref name='moses-bio'/><br><small>World Bank.</small>
 
* Mapping key populations for [[HIV]] prevention in Sri Lanka.<ref name='moses-bio'/><br><small>World Bank.</small>
  
== Recent publications ==
+
{{PUB}}
* Prevalence and risk factors for human papillomavirus infection by penile site in [[uncircumcised]] Kenyan men.<ref>{{REFjournal
+
* {{REFjournal
 
  |last=Smith
 
  |last=Smith
 
  |init=JS
 
  |init=JS
Line 127: Line 127:
 
  |last3=Hudgens
 
  |last3=Hudgens
 
  |init3=MG
 
  |init3=MG
 +
|last4=Bailey
 +
|first4=Robert C.
 +
|init4=RC
 +
|author4-link=Robert C. Bailey
 +
|last5=Agot
 +
|init5=K
 +
|last6=Ndinya-Achola
 +
|init6=JO
 +
|last7=Moses
 +
|init7=S
 +
|author7-link=Stephen Moses
 
  |etal=yes
 
  |etal=yes
 
  |date=2010-01
 
  |date=2010-01
Line 139: Line 150:
 
  |DOI=10.1002/ijc.24770
 
  |DOI=10.1002/ijc.24770
 
  |accessdate=
 
  |accessdate=
}}</ref><br><small>Smith JS, Hudgens MG, '''[[Robert C. Bailey|Bailey RC]]''', Agot K, Ndinya-Achola JO, Moses S, et al. Int J Cancer 2010; 126: 572-7.</small>
+
}}
* Top Achievements in Health Research: Male circumcision: a new approach to reducing [[HIV]] transmission.<ref>{{REFjournal
+
* {{REFjournal
 
  |last=Moses
 
  |last=Moses
 
  |init=S
 
  |init=S
 
  |author-link=Stephen Moses
 
  |author-link=Stephen Moses
 
  |date=2009-10
 
  |date=2009-10
  |title=Male circumcision: a new approach to reducing HIV transmission
+
  |title=Top Achievements in Health Research: Male circumcision: a new approach to reducing HIV transmission
  |journal=CMAJ
+
  |journal=CIHR/CMAJ
 
  |volume=181
 
  |volume=181
 
  |issue=8
 
  |issue=8
Line 155: Line 166:
 
  |DOI=10.1503/cmaj.090809
 
  |DOI=10.1503/cmaj.090809
 
  |accessdate=
 
  |accessdate=
}}</ref><br><small>Moses S. CIHR/CMAJ 2009; 181: E134-5.</small>
+
}}
* Does sex in the early period after circumcision increase [[HIV]]-seroconversion risk? Pooled analysis of adult male circumcision clinical trials.<ref>{{REFjournal
+
* {{REFjournal
 
  |last=Mehta
 
  |last=Mehta
 
  |init=SD
 
  |init=SD
 
  |last2=Gray
 
  |last2=Gray
 
  |init2=RH
 
  |init2=RH
 +
|author2-link=Ronald H. Gray
 
  |last3=Auvert
 
  |last3=Auvert
 
  |init3=B
 
  |init3=B
 +
|author3-link=Bertran Auvert
 +
|last4=Moses
 +
|init4=S
 +
|author4-link=Stephen Moses
 +
|last5=Kigozi
 +
|init5=G
 +
|author5-link=Godfrey Kigozi
 +
|last6=Taljaard
 +
|init6=D
 +
|last7=Puren
 +
|init7=A
 +
|last8=Agot
 +
|init8=K
 +
|last9=Serwadda
 +
|init9=D
 +
|other=Parker CB, [[Maria Wawer|Wawer MJ]], [[Robert C. Bailey|Bailey RC]]
 
  |etal=yes
 
  |etal=yes
 
  |date=2007-07
 
  |date=2007-07
Line 176: Line 204:
 
  |accessdate=
 
  |accessdate=
 
}}
 
}}
</ref><br><small>Mehta SD, '''[[Ronald Gray|Gray RH]]''', '''[[Bertran Auvert|Auvert B]]''', Moses S , Kigozi G, Taljaard D, Puren A, Agot K, Serwadda D, Parker CB, '''[[Maria Wawer|Wawer MJ]]''', '''[[Robert C. Bailey|Bailey RC]]'''. AIDS 2009; 23: 1557-64.</small>
+
* {{RCT Bailey et al 2007}}
* Male circumcision for [[HIV]] prevention in young men in Kisumu, Kenya: a randomised controlled trial.<ref>{{REFjournal
+
* {{REFjournal
|last=Bailey
 
|init=RC
 
|last2=Moses
 
|init2=S
 
|author2-link=Stephen Moses
 
|last3=Parker
 
|init3=CB
 
|etal=yes
 
|date=2007-02
 
|title=Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial
 
|journal=Lancet
 
|volume=369
 
|issue=9562
 
|pages=643–56
 
|url=
 
|pubmedID=17321310
 
|DOI=10.1016/S0140-6736(07)60312-2
 
|accessdate=
 
}}
 
</ref><br><small>'''[[Robert C. Bailey|Bailey RC]]''', Moses S , Parker CB, Agot K, Maclean I, Krieger JN, et al. Lancet 2007; 369: 643-56.</small>
 
* Modelling the public health impact of male circumcision for [[HIV]] prevention in high prevalence areas in Africa.<ref>{{REFjournal
 
 
  |last=Nagelkerke
 
  |last=Nagelkerke
  |init=NJ
+
  |init=NJD
 
  |last2=Moses
 
  |last2=Moses
 
  |init2=S
 
  |init2=S
Line 208: Line 215:
 
  |last4=Bailey
 
  |last4=Bailey
 
  |init4=RC
 
  |init4=RC
 +
|author4-link=Robert C. Bailey
 
  |date=2007
 
  |date=2007
 
  |title=Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa
 
  |title=Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa
Line 219: Line 227:
 
  |DOI=10.1186/1471-2334-7-16
 
  |DOI=10.1186/1471-2334-7-16
 
  |accessdate=
 
  |accessdate=
}}</ref><br><small>Nagelkerke NJD, Moses S, de Vlas S, '''[[Robert C. Bailey|Bailey RC]]'''. BMC Infect Dis 2007; 7: 16.</small>
+
}}
* Adult male circumcision outcomes: experience in a developing country setting.<ref>{{REFjournal
+
* {{REFjournal
 
  |last=Krieger
 
  |last=Krieger
 
  |init=JN
 
  |init=JN
 
  |last2=Bailey
 
  |last2=Bailey
 
  |init2=RC
 
  |init2=RC
  |last3=Opeya
+
|author2-link=Robert C. Bailey
  |init3=JC
+
  |last3=Agot
 +
  |init3=K
 +
|last4=Parker
 +
|init4=C
 +
|last5=Ndinya-Achola
 +
|init5=JO
 +
|last6=Moses
 +
|init6=S
 +
|author6-link=Stephen Moses
 
  |etal=yes
 
  |etal=yes
 
  |date=2007
 
  |date=2007
 
  |title=Adult male circumcision outcomes: experience in a developing country setting
 
  |title=Adult male circumcision outcomes: experience in a developing country setting
  |journal=Urol. Int.
+
  |journal=Urol Int
 
  |volume=78
 
  |volume=78
 
  |issue=3
 
  |issue=3
Line 239: Line 255:
 
  |accessdate=
 
  |accessdate=
 
}}
 
}}
</ref><br><small>Krieger J, '''[[Robert C. Bailey|Bailey RC]]''', Agot K, Parker C, Ndinya-Achola JO, Moses S, et al. Urol Int 2007; 78: 235-40.</small>
 
  
 
{{SEEALSO}}
 
{{SEEALSO}}
 
* [[Bias]]
 
* [[Bias]]
 +
* [[Canada]]
 
* [[Circumcised doctors]]
 
* [[Circumcised doctors]]
  
Line 253: Line 269:
  
 
[[Category:Researcher]]
 
[[Category:Researcher]]
 +
[[Category:Author]]
  
 
[[Category:Canada]]
 
[[Category:Canada]]

Latest revision as of 14:57, 8 July 2024

Stephen Moses, Professor, Departments of Medical Microbiology, Community Health Sciences and Medicine. Stephen Moses has been a circumcision proponent since at least 1994.[1] Moses (along with Robert C. Bailey) was responsible for one of the three major African circumcision trials (funded by NIAID and the Canadian Institutes of Health Research)[2] which are being used by the World Health Organization (under the guide of UNAIDS) to endorse circumcision as an HIV prevention method.[3]

Stephen Moses.jpg
Stephen Moses
Associates With:
Gilgal Society
Circlist
Colleagues & Benefactors:
Daniel T. Halperin
Edgar J. Schoen
Robert C. Bailey
Bertran Auvert
Maria J. Wawer
Brian J. Morris
Avahan project
Funded by The World Bank

Contents

Interests

According to Stephen's bio, his interest is in biological and behavioural risk factors for STI/HIV transmission.[4] Moses has been an advocate of circumcision since at least 1994.[1]

RCT in Kenya

Three trials were funded by the American National Institutes of Health.[5]Of the three RCTs being used by the WHO to endorse circumcision as HIV prevention, Stephen Moses and Robert C. Bailey headed the RCT that was carried out in Kenya.[6] Moses obviously brought his pre-existing bias in favor of male circumcision into the trial, so he did not start from a neutral position.

Moses' research on circumcision protection from HIV infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent relative reduction in HIV was claimed, the absolute reduction was a statistically insignificant 1.3 percent.[7] Garenne & Matthews (2019) report that circumcised men have as much HIV infection as intact men.[8]

Active projects

Publications

See also

References

  1. a b   Moses S, Plummer FA, Bradley JE, Ndinya-Achola JO, Nagelkerke NJ, Ronald AR. The association between lack of male circumcision and risk for HIV infection: a review of the epidemiological data. Sex Transm Dis. 1994; 21: 201-210.
  2.   Krieger JN, Bailey RC, Opeya J, et al. Adult male circumcision: results of a standardized procedure in Kisumu District, Kenya. BJU Int.. November 2005; 96(7): 1109–13. PMID. DOI.
  3.   World Health Organization (27 March 2007). WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention. Retrieved 23 February 2011.
  4. a b c d e f   Moses, Stephen. Dr. Stephen Moses, University of Manitoba. Retrieved 23 February 2011.
  5.   (2016). HIV/AIDS, Doctors Opposing Circumcision (D.O.C.). Retrieved 23 March 2020.
    Quote: ...funding from the United States National Institutes of Health to conduct randomized controlled trials (RCTs) in Africa.
  6.   Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet. 24 February 2007; 369(9562): 643–56. PMID. DOI. Retrieved 31 December 2021.
  7.   Boyle GJ, Hill G. Sub-Saharan African randomised clinical trials into male circumcision and HIV transmission: Methodological, ethical and legal concerns  . Thompson Reuter. December 2011; 19(2): 316-34. PMID. Retrieved 30 December 2020.
  8.   Garenne M, Matthews A. Voluntary medical male circumcision and HIV in Zambia: expectations and observations. J Biosoc Science. 1 October 2019; 14: 1-13. PMID. DOI. Retrieved 25 March 2020.